182 related articles for article (PubMed ID: 20150388)
1. Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab.
Gan HK; Azad A; Cher L; Mitchell PL
Neuro Oncol; 2010 Feb; 12(2):212-5. PubMed ID: 20150388
[TBL] [Abstract][Full Text] [Related]
2. Secondary neurolymphomatosis detected by whole-body diffusion-weighted magnetic resonance imaging: a case report.
Tanaka H; Yoshino K; Sakaida E; Hashimoto S; Takeda Y; Kawajiri C; Takagi T; Nakaseko C
J Clin Exp Hematop; 2013; 53(3):221-6. PubMed ID: 24369224
[TBL] [Abstract][Full Text] [Related]
3. [Neurolymphomatosis: diagnosis of extension and assessment of response to treatment with PET-CT].
Durán C; Infante JR; Serrano J; Rayo JI; García L; Domínguez ML; Sánchez R
Rev Esp Med Nucl; 2009; 28(6):295-8. PubMed ID: 19864049
[TBL] [Abstract][Full Text] [Related]
4. A rare case of primary high-grade large B-cell lymphoma of the sciatic nerve.
Advani P; Paulus A; Murray P; Jiang L; Goff R; Pooley R; Jain M; Garner H; Foran J
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e117-20. PubMed ID: 25617034
[No Abstract] [Full Text] [Related]
5. Primary sciatic nerve lymphoma: a case report and review of the literature.
Descamps MJ; Barrett L; Groves M; Yung L; Birch R; Murray NM; Linch DC; Lunn MP; Reilly MM
J Neurol Neurosurg Psychiatry; 2006 Sep; 77(9):1087-9. PubMed ID: 16914759
[TBL] [Abstract][Full Text] [Related]
6. Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era.
Khurana A; Novo M; Nowakowski GS; Ristow KM; Spinner RJ; Hunt CH; King RL; Lachance DH; Habermann TM; Micallef IN; Johnston PB
Blood Adv; 2021 Mar; 5(5):1379-1387. PubMed ID: 33661298
[TBL] [Abstract][Full Text] [Related]
7. [Primary neurolymphomatosis of the cervical nerve root].
Miki M; Masaki Y; Nakamura T; Iwao H; Nakajima A; Sakai T; Sawaki T; Kawanami T; Kaito M; Kurose N; Fujita Y; Tanaka M; Fukushima T; Hirose Y; Umehara H
Rinsho Ketsueki; 2010 Jul; 51(7):564-7. PubMed ID: 20693778
[TBL] [Abstract][Full Text] [Related]
8. Reversal of neurological deficit after chemotherapy in BCL-6-positive neurolymphomatosis. Case report.
Peruzzi P; Ray-Chaudhuri A; Slone WH; Mekhjian HS; Porcu P; Chiocca E
J Neurosurg; 2009 Aug; 111(2):247-51. PubMed ID: 19216652
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
10. Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.
Bishton MJ; Hughes S; Richardson F; James E; Bessell E; Sovani V; Ganatra R; Haynes AP; McMillan AK; Fox CP
Br J Haematol; 2016 Jan; 172(2):246-54. PubMed ID: 26577576
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
Ferrara F; Ravasio R
Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
[TBL] [Abstract][Full Text] [Related]
12. Gastric diffuse large B cell lymphoma presenting as paraneoplastic cerebellar degeneration: case report and review of literature.
Lakshmaiah KC; Viveka BK; Anil Kumar N; Saini ML; Sinha S; Saini KS
J Egypt Natl Canc Inst; 2013 Dec; 25(4):231-5. PubMed ID: 24207096
[TBL] [Abstract][Full Text] [Related]
13. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
Knight C; Hind D; Brewer N; Abbott V
Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
[TBL] [Abstract][Full Text] [Related]
14. Peripheral neurolymphomatosis with tracheal asphyxia: a case report and literature review.
Liu Z; Jiang T; Hou N; Jia Y
BMC Neurol; 2015 Aug; 15():149. PubMed ID: 26298453
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of aggressive HIV-associated non-Hodgkin's lymphoma with combination chemotherapy, biotherapy with rituximab and HAART: presentation of a therapeutic option.
Klepfish A; Schattner A; Shvidel L; Shtalrid M; Haran M; Bentwich Z; Berrebi A
Leuk Lymphoma; 2003 Feb; 44(2):349-51. PubMed ID: 12688356
[TBL] [Abstract][Full Text] [Related]
16. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab.
Feugier P; Virion JM; Tilly H; Haioun C; Marit G; Macro M; Bordessoule D; Recher C; Blanc M; Molina T; Lederlin P; Coiffier B
Ann Oncol; 2004 Jan; 15(1):129-33. PubMed ID: 14679132
[TBL] [Abstract][Full Text] [Related]
17. [Primary hepatic lymphoma - favorable outcome with chemotherapy plus rituximab].
Serrano-Navarro I; Rodríguez-López JF; Navas-Espejo R; Pérez-Jacoiste MA; Martínez-González MA; Grande C; Prieto S
Rev Esp Enferm Dig; 2008 Nov; 100(11):724-8. PubMed ID: 19159179
[TBL] [Abstract][Full Text] [Related]
18. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.
Dunleavy K; Little RF; Pittaluga S; Grant N; Wayne AS; Carrasquillo JA; Steinberg SM; Yarchoan R; Jaffe ES; Wilson WH
Blood; 2010 Apr; 115(15):3017-24. PubMed ID: 20130244
[TBL] [Abstract][Full Text] [Related]
19. Disseminated Lymphoma Evolving into Neurolymphomatosis during Mid-cycle of Chemotherapy Detected by (18)F-FDG PET/CT.
Tong AK; Neo SH; Kok TY
Ann Acad Med Singap; 2015 Nov; 44(11):545-7. PubMed ID: 27089963
[No Abstract] [Full Text] [Related]
20. Diffuse aggressive lymphoma.
Fisher RI; Miller TP; O'Connor OA
Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
